LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset (ID:20249)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | SB590885 | 3.33 | uM | LJP5 | 72 | hr | 1334 | 4161 | 4033 | 1.0319 | 1.0398 |
| MCF7 | Lapatinib | 0.37 | uM | LJP6 | 72 | hr | 1389 | 5614 | 5445 | 1.0316 | 1.0319 |
| MCF7 | Nilotinib | 0.04 | uM | LJP5 | 72 | hr | 1389 | 6100 | 5905 | 1.0313 | 1.0276 |
| SK-BR-3 | Vemurafenib | 1.11 | uM | LJP5 | 72 | hr | 2543 | 5932 | 5752 | 1.0313 | 1.0529 |
| BT-20 | Nintedanib | 0.04 | uM | LJP6 | 72 | hr | 1334 | 4047 | 3925 | 1.0311 | 1.0391 |
| BT-20 | Withaferin A | 0.12 | uM | LJP6 | 72 | hr | 1334 | 4046 | 3925 | 1.0310 | 1.0394 |
| BT-20 | XMD11-85h | 1.11 | uM | LJP6 | 72 | hr | 1334 | 4046 | 3925 | 1.0309 | 1.0394 |
| MCF 10A | MK2206 | 0.04 | uM | LJP6 | 72 | hr | 1694 | 11562 | 11217 | 1.0307 | 1.0223 |
| MCF 10A | CHIR-99021 | 0.04 | uM | LJP6 | 72 | hr | 1694 | 11560 | 11217 | 1.0305 | 1.0221 |
| MDA-MB-231 | Ruxolitinib | 0.37 | uM | LJP5 | 72 | hr | 1311 | 5229 | 5079 | 1.0299 | 1.0301 |
| SK-BR-3 | Enzastaurin | 0.12 | uM | LJP5 | 72 | hr | 2543 | 5924 | 5752 | 1.0298 | 1.0505 |
| MCF 10A | JW-7-24-1 | 0.37 | uM | LJP6 | 72 | hr | 1694 | 11550 | 11217 | 1.0298 | 1.0217 |
| MCF7 | AZD-6482 | 0.04 | uM | LJP5 | 72 | hr | 1389 | 6084 | 5905 | 1.0297 | 1.0278 |
| SK-BR-3 | PD184352 | 0.12 | uM | LJP5 | 72 | hr | 2543 | 5922 | 5752 | 1.0296 | 1.0502 |
| MCF7 | Celastrol | 0.12 | uM | LJP6 | 72 | hr | 1389 | 5607 | 5445 | 1.0295 | 1.0296 |
| BT-20 | Nintedanib | 0.12 | uM | LJP6 | 72 | hr | 1334 | 4041 | 3925 | 1.0295 | 1.0373 |
| MDA-MB-231 | PIK-93 | 0.12 | uM | LJP5 | 72 | hr | 1311 | 5226 | 5079 | 1.0295 | 1.0296 |
| MDA-MB-231 | Sorafenib | 1.11 | uM | LJP6 | 72 | hr | 1311 | 5080 | 4935 | 1.0294 | 1.0305 |
| SK-BR-3 | NVP-AEW541 | 0.04 | uM | LJP5 | 72 | hr | 2543 | 5921 | 5752 | 1.0294 | 1.0499 |
| SK-BR-3 | Sorafenib | 0.37 | uM | LJP6 | 72 | hr | 2543 | 5574 | 5418 | 1.0293 | 1.0551 |
| MDA-MB-231 | Brivanib | 0.04 | uM | LJP5 | 72 | hr | 1311 | 5226 | 5079 | 1.0291 | 1.0294 |
| MCF 10A | R406 | 0.04 | uM | LJP6 | 72 | hr | 1694 | 11540 | 11217 | 1.0289 | 1.0210 |
| BT-20 | Buparlisib | 0.04 | uM | LJP5 | 72 | hr | 1334 | 4150 | 4033 | 1.0287 | 1.0355 |
| MCF7 | PIK-93 | 0.12 | uM | LJP5 | 72 | hr | 1389 | 6076 | 5905 | 1.0287 | 1.0272 |
| BT-20 | GSK1059615 | 0.04 | uM | LJP5 | 72 | hr | 1334 | 4146 | 4033 | 1.0285 | 1.0361 |